Plasma levels of platelet-derived growth factor BB and transforming growth factor in patients with failed hip prostheses

Elisabetta Cenni, Lucia Savarino, Diego Antonioli, Andrea Pellacani, Armando Giunti, Nicola Baldini

Research output: Contribution to journalArticle

Abstract

Background: The role of growth factors in prosthesis loosening is unclear. We evaluated the levels of platelet-derived growth factor BB (PDGF-BB), transforming growth factors β1 (TGF-β1) and β2 (TGF-β2), both before and after activation, in patients with aseptic loosening of their hip prosthesis. Patients and methods: 26 patients with loosened hip implants were compared with 21 patients who had stable hip prostheses, and 28 patients undergoing primary hip replacement The plasma levels of the growth factors were analyzed by enzyme immunoassay. TGF-β1 and TGF-β2 were determined both before and after activation. Results: Patients with aseptic loosening had significantly lower PDGF-BB levels than patients undergoing primary hip replacement, and significantly lower TGF-β2 levels than patients with a stable implant. Patients with stable prostheses had significantly higher TGF-β1 and TGF-β2 levels than patients undergoing primary hip replacement. Interpretation: It is possible that the prosthetic implant itself causes a local increase in PDGF-BB, TGF-β1 and TGF-β2, released by osteoblasts and other cells in the microenvironment. The plasma PDGF-BB measured does not correspond to local release, which is probably due to local consumption or degradation. The consumption of PDGF-BB is low in stable implants, and TGF-β1 and TGF-β2 levels increase during bone formation. In loosening, PDGF-BB consumption is higher and causes a significant reduction in plasma levels as compared to presurgery. The formation of poor-quality bone may be related to the scarce increase in TGF-β1 and TGF-β2. In conclusion, compared with patients with a stable implant, a reduction in bone-forming growth factors appears to occur in individuals with aseptic loosening.

Original languageEnglish
Pages (from-to)61-66
Number of pages6
JournalActa Orthopaedica Scandinavica
Volume76
Issue number1
DOIs
Publication statusPublished - Feb 2005

Fingerprint

Hip Prosthesis
Transforming Growth Factors
Hip
Intercellular Signaling Peptides and Proteins
platelet-derived growth factor BB
Prosthesis Failure
Cellular Microenvironment
Bone Development
Osteoblasts
Immunoenzyme Techniques
Osteogenesis
Prostheses and Implants

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Plasma levels of platelet-derived growth factor BB and transforming growth factor in patients with failed hip prostheses. / Cenni, Elisabetta; Savarino, Lucia; Antonioli, Diego; Pellacani, Andrea; Giunti, Armando; Baldini, Nicola.

In: Acta Orthopaedica Scandinavica, Vol. 76, No. 1, 02.2005, p. 61-66.

Research output: Contribution to journalArticle

Cenni, Elisabetta ; Savarino, Lucia ; Antonioli, Diego ; Pellacani, Andrea ; Giunti, Armando ; Baldini, Nicola. / Plasma levels of platelet-derived growth factor BB and transforming growth factor in patients with failed hip prostheses. In: Acta Orthopaedica Scandinavica. 2005 ; Vol. 76, No. 1. pp. 61-66.
@article{79a772e7fa704626804a1ae0283e145c,
title = "Plasma levels of platelet-derived growth factor BB and transforming growth factor in patients with failed hip prostheses",
abstract = "Background: The role of growth factors in prosthesis loosening is unclear. We evaluated the levels of platelet-derived growth factor BB (PDGF-BB), transforming growth factors β1 (TGF-β1) and β2 (TGF-β2), both before and after activation, in patients with aseptic loosening of their hip prosthesis. Patients and methods: 26 patients with loosened hip implants were compared with 21 patients who had stable hip prostheses, and 28 patients undergoing primary hip replacement The plasma levels of the growth factors were analyzed by enzyme immunoassay. TGF-β1 and TGF-β2 were determined both before and after activation. Results: Patients with aseptic loosening had significantly lower PDGF-BB levels than patients undergoing primary hip replacement, and significantly lower TGF-β2 levels than patients with a stable implant. Patients with stable prostheses had significantly higher TGF-β1 and TGF-β2 levels than patients undergoing primary hip replacement. Interpretation: It is possible that the prosthetic implant itself causes a local increase in PDGF-BB, TGF-β1 and TGF-β2, released by osteoblasts and other cells in the microenvironment. The plasma PDGF-BB measured does not correspond to local release, which is probably due to local consumption or degradation. The consumption of PDGF-BB is low in stable implants, and TGF-β1 and TGF-β2 levels increase during bone formation. In loosening, PDGF-BB consumption is higher and causes a significant reduction in plasma levels as compared to presurgery. The formation of poor-quality bone may be related to the scarce increase in TGF-β1 and TGF-β2. In conclusion, compared with patients with a stable implant, a reduction in bone-forming growth factors appears to occur in individuals with aseptic loosening.",
author = "Elisabetta Cenni and Lucia Savarino and Diego Antonioli and Andrea Pellacani and Armando Giunti and Nicola Baldini",
year = "2005",
month = "2",
doi = "10.1080/00016470510030337",
language = "English",
volume = "76",
pages = "61--66",
journal = "Acta Orthopaedica Scandinavica",
issn = "0001-6470",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

TY - JOUR

T1 - Plasma levels of platelet-derived growth factor BB and transforming growth factor in patients with failed hip prostheses

AU - Cenni, Elisabetta

AU - Savarino, Lucia

AU - Antonioli, Diego

AU - Pellacani, Andrea

AU - Giunti, Armando

AU - Baldini, Nicola

PY - 2005/2

Y1 - 2005/2

N2 - Background: The role of growth factors in prosthesis loosening is unclear. We evaluated the levels of platelet-derived growth factor BB (PDGF-BB), transforming growth factors β1 (TGF-β1) and β2 (TGF-β2), both before and after activation, in patients with aseptic loosening of their hip prosthesis. Patients and methods: 26 patients with loosened hip implants were compared with 21 patients who had stable hip prostheses, and 28 patients undergoing primary hip replacement The plasma levels of the growth factors were analyzed by enzyme immunoassay. TGF-β1 and TGF-β2 were determined both before and after activation. Results: Patients with aseptic loosening had significantly lower PDGF-BB levels than patients undergoing primary hip replacement, and significantly lower TGF-β2 levels than patients with a stable implant. Patients with stable prostheses had significantly higher TGF-β1 and TGF-β2 levels than patients undergoing primary hip replacement. Interpretation: It is possible that the prosthetic implant itself causes a local increase in PDGF-BB, TGF-β1 and TGF-β2, released by osteoblasts and other cells in the microenvironment. The plasma PDGF-BB measured does not correspond to local release, which is probably due to local consumption or degradation. The consumption of PDGF-BB is low in stable implants, and TGF-β1 and TGF-β2 levels increase during bone formation. In loosening, PDGF-BB consumption is higher and causes a significant reduction in plasma levels as compared to presurgery. The formation of poor-quality bone may be related to the scarce increase in TGF-β1 and TGF-β2. In conclusion, compared with patients with a stable implant, a reduction in bone-forming growth factors appears to occur in individuals with aseptic loosening.

AB - Background: The role of growth factors in prosthesis loosening is unclear. We evaluated the levels of platelet-derived growth factor BB (PDGF-BB), transforming growth factors β1 (TGF-β1) and β2 (TGF-β2), both before and after activation, in patients with aseptic loosening of their hip prosthesis. Patients and methods: 26 patients with loosened hip implants were compared with 21 patients who had stable hip prostheses, and 28 patients undergoing primary hip replacement The plasma levels of the growth factors were analyzed by enzyme immunoassay. TGF-β1 and TGF-β2 were determined both before and after activation. Results: Patients with aseptic loosening had significantly lower PDGF-BB levels than patients undergoing primary hip replacement, and significantly lower TGF-β2 levels than patients with a stable implant. Patients with stable prostheses had significantly higher TGF-β1 and TGF-β2 levels than patients undergoing primary hip replacement. Interpretation: It is possible that the prosthetic implant itself causes a local increase in PDGF-BB, TGF-β1 and TGF-β2, released by osteoblasts and other cells in the microenvironment. The plasma PDGF-BB measured does not correspond to local release, which is probably due to local consumption or degradation. The consumption of PDGF-BB is low in stable implants, and TGF-β1 and TGF-β2 levels increase during bone formation. In loosening, PDGF-BB consumption is higher and causes a significant reduction in plasma levels as compared to presurgery. The formation of poor-quality bone may be related to the scarce increase in TGF-β1 and TGF-β2. In conclusion, compared with patients with a stable implant, a reduction in bone-forming growth factors appears to occur in individuals with aseptic loosening.

UR - http://www.scopus.com/inward/record.url?scp=14744292839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14744292839&partnerID=8YFLogxK

U2 - 10.1080/00016470510030337

DO - 10.1080/00016470510030337

M3 - Article

C2 - 15788309

AN - SCOPUS:14744292839

VL - 76

SP - 61

EP - 66

JO - Acta Orthopaedica Scandinavica

JF - Acta Orthopaedica Scandinavica

SN - 0001-6470

IS - 1

ER -